Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
A Randomised, Double-blind, Placebo Controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients With Locally Advanced and/or Metastatic Renal Cell Carcinoma
Sponsor: GlaxoSmithKline
A PHASE3 clinical study on Carcinoma, Renal Cell, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 7 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Apr 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Athens, Greece, Bangalore, India, Bebington, Wirral, United Kingdom, Beijing, China, Belfast, United Kingdom, Belo Horizonte, Brazil, Bratislava, Slovakia, Brno, Czechia, Capital Federal, Argentina, Casalpusterlengo (LO), Italy and 75 more location s